Clinical Trial Resources

Explore hypoparathyroidism research opportunities and learn how you can contribute to advancing treatment options

Advancing Research

Clinical trials help researchers understand hypoparathyroidism better and develop new treatment options that could benefit millions of patients.

Patient Power

Your participation in clinical trials directly impacts the future of hypoparathyroidism treatment and helps create better care options for everyone.

Community Impact

Every patient who participates in research contributes to a stronger hypoparathyroidism community and helps us move closer to better treatments.

Active Clinical Trials

TRIAL IDENTIFIER

NCT05793853

STUDY TYPE

Natural History Study

PRINCIPAL INVESTIGATOR

Dr. Mishaela Ruth Rubin

Natural History Study of Hypoparathyroidism

Study Overview

This comprehensive natural history study examines the long-term complications and disease progression of hypoparathyroidism. The research helps physicians and patients understand the condition better and make informed decisions about treatment options, including whether conventional treatment with calcium and vitamin D is appropriate for individual patients.

Why This Study Matters

As new treatment options like Yorvipath emerge, understanding the long-term complications of hypoparathyroidism is crucial. This study provides the evidence base that helps both physicians and patients make informed decisions about their care pathways and treatment strategies.

Key Research Areas

  • Long-term complications of hypoparathyroidism
  • Disease progression and natural history
  • Impact of different treatment approaches
  • Quality of life outcomes for patients
  • Paradigm shift in treatment understanding

"This study is particularly important to the hypoparathyroidism community as it underscores the needed paradigm shift surrounding treatment and understanding of the condition. With new treatment options on the horizon, understanding the long-term complications can help both physicians and patients make informed decisions about their care pathways."

— Bari Vapnek

Director of Marketing and Public Relations, HypoPARAthyroidism Association, Inc.

TRIAL IDENTIFIER

NCT06961071

INSTITUTION

UCSF

STUDY TYPE

Clinical Research

UCSF Hypoparathyroidism Clinical Trial

Study Overview

This clinical trial at UCSF focuses on advancing hypoparathyroidism research and treatment options. The study aims to improve patient outcomes and expand our understanding of the condition.

Study Significance

UCSF's research contributes to the growing body of evidence supporting better treatment approaches for hypoparathyroidism patients. Your participation helps advance medical science and improve care options.

How to Participate

1

Learn More

Review the study details on ClinicalTrials.gov to understand the research and eligibility criteria

2

Check Eligibility

Review the inclusion/exclusion criteria to determine if you qualify for the study

3

Contact Researchers

Reach out to the study team through ClinicalTrials.gov to express your interest in participating

4

Make a Difference

Participate in the study and contribute to advancing hypoparathyroidism research and treatment options

Important Information

Clinical Trial Participation

  • Clinical trials are voluntary. You can withdraw at any time without penalty.
  • All participants must provide informed consent before enrollment.
  • Research teams follow strict ethical guidelines and safety protocols.
  • Discuss any trial participation with your healthcare provider first.

Medical Disclaimer

This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before participating in any clinical trial or making decisions about your treatment. If you experience a medical emergency, please call 911 or seek immediate medical attention.

Ready to Make a Difference?

Your participation in clinical trials can help advance hypoparathyroidism research and create better treatment options for patients worldwide.